BioXcel Therapeutics Announces Oral and Poster Presentations at the 2024 American Society of Clinical Psychopharmacology Annual Meeting
BTAI Stock | USD 0.41 0.04 8.89% |
Under 67% of BioXcel Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding BioXcel Therapeutics suggests that many traders are alarmed. BioXcel Therapeutics' investing sentiment shows overall attitude of investors towards BioXcel Therapeutics.
BioXcel |
NEW HAVEN, Conn., May 21, 2024 -- BioXcel Therapeutics, Inc. , a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that Rob Risinger, M.D., Chief Medical Officer of Neuroscience, will deliver oral and poster presentations at the 2024 American Society of Clinical Psychopharmacology Annual Meeting. The meeting will take place May 28 to 31, 2024 in Miami Beach, FL
Read at finance.yahoo.com
BioXcel Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards BioXcel Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
BioXcel Therapeutics Fundamental Analysis
We analyze BioXcel Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioXcel Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioXcel Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Target Price
Target Price Comparative Analysis
BioXcel Therapeutics is currently under evaluation in target price category among its peers.
BioXcel Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with BioXcel Therapeutics stock to make a market-neutral strategy. Peer analysis of BioXcel Therapeutics could also be used in its relative valuation, which is a method of valuing BioXcel Therapeutics by comparing valuation metrics with similar companies.
Peers
BioXcel Therapeutics Related Equities
XFOR | X4 Pharmaceuticals | 11.43 | ||||
HEPA | Hepion Pharmaceuticals | 4.69 | ||||
ELEV | Elevation Oncology | 3.23 | ||||
DAWN | Day One | 1.53 | ||||
EXEL | Exelixis | 1.48 | ||||
MREO | Mereo BioPharma | 1.40 | ||||
ABOS | Acumen Pharmaceuticals | 0.44 | ||||
INZY | Inozyme Pharma | 0.37 | ||||
TGTX | TG Therapeutics | 0.57 | ||||
APLS | Apellis Pharmaceuticals | 0.62 | ||||
MDGL | Madrigal Pharmaceuticals | 0.98 | ||||
TERN | Terns Pharmaceuticals | 1.58 | ||||
VKTX | Viking Therapeutics | 2.88 | ||||
AMLX | Amylyx Pharmaceuticals | 3.48 |
Complementary Tools for BioXcel Stock analysis
When running BioXcel Therapeutics' price analysis, check to measure BioXcel Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioXcel Therapeutics is operating at the current time. Most of BioXcel Therapeutics' value examination focuses on studying past and present price action to predict the probability of BioXcel Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioXcel Therapeutics' price. Additionally, you may evaluate how the addition of BioXcel Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. |